Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer

Medical Hypotheses

Volumn 78, Issue 3, 2012, Pages 407-409

  Jia, Lin ^a   Zhang, Hui ^a   Qu, Xun ^a   Deng, Biping ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ARTICLE; BLOOD ANALYSIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; ENDOMETRIOID CARCINOMA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; MOLECULAR DIAGNOSIS; MUCINOUS CARCINOMA; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEROSA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

FEMALE; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEOMICS;

EID: 84856430431     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.11.017     Document Type: Article

References (27)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Holschneider C.H., Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000, 19:3-10.
3. Adib T.R., Henderson S., Perrett C., et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004, 90:686-692.
4. Nicosia S.V., Bai W., Cheng J.Q., Coppola D., Kruk P.A. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 2003, 17:927-943.
5. Cowley S.M., Hoare S., Mosselman S., Parker M.G. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997, 272:19858-19862.
6. Schwartz D.R., Kardia S.L., Shedden K.A., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002, 62:4722-4729.
7. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005, 18(Suppl. 2):S19-S32.
8. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511-1518.
9. Singer G., Stohr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29:218-224.
10. Zhang H., Kong B., Qu X., Jia L., Deng B., Yang Q. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 2006, 102:61-66.
11. Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001, 276:27371-27375.
12. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005, 102:7677-7682.
13. Zhang Z., Bast R.C., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890.
14. Wu S.P., Lin Y.W., Lai H.C., Chu T.Y., Kuo Y.L., Liu H.S. SELDI-TOF MS profiling of plasma proteins in ovarian cancer. Taiwan J Obstet Gynecol 2006, 45:26-32.
15. Wang J., Zhang X., Ge X., Guo H., Xiong G., Zhu Y. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol 2008, 111:111-119.
16. Boyd J., Sonoda Y., Federici M.G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283:2260-2265.
17. Schaner M.E., Ross D.T., Ciaravino G., et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003, 14:4376-4386.
18. Marchini S., Mariani P., Chiorino G., et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res 2008, 14:7850-7860.
19. Iorio M.V., Visone R., Di Leva G., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
20. Luo J., Qian J.H., Yu J.K., Zheng S., Xie X., Lu W.G. Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry. Eur J Gynaecol Oncol 2008, 29:233-238.
21. Cadron I., Van Gorp T., Moerman P., Waelkens E., Vergote I. Proteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS. Methods Mol Biol 2011, 755:155-163.
22. Cadron I., Van Gorp T., Amant F., et al. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res 2009, 29:1039-1045.
23. Zhu Y., Wu R., Sangha N., et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006, 6:5846-5856.
24. Yanagisawa K., Shyr Y., Xu B.J., et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003, 362:433-439.
25. Wallin E., von Heijne G. Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. Protein Sci 1998, 7:1029-1038.
26. Hopkins A.L., Groom C.R. The druggable genome. Nat Rev Drug Discov 2002, 1:727-730.
27. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378.